Figure 2

TAK-242 administration results in reduced CD68+ macrophage accumulation at week 2. (A) Immunohistochemical analysis showed no significant differences in the number of CD4+ , CD8+ or Foxp3+ T cells between the TAK-242-treated group and vehicle-treated group. (B) Immunofluorescence staining showed a reduction in CD68+ macrophages in TAK-242-treated allografts as compared with vehicle-treated allografts. (n = 8–9 mice for per group, 5 cross-sections for per graft, *P < 0.05, scale bar = 20 μm).